CAMPUS è l'Archivio istituzionale delle pubblicazioni scientifiche dell’Università di Camerino. E’ un sistema aperto, pubblico e interoperabile che raccoglie, conserva ed espone i dati relativi alle attività e ai prodotti della ricerca dell’Ateneo con lo scopo di migliorarne la visibilità e di favorirne l’impatto a livello nazionale e internazionale.
EnglishA recently developed, adaptive constant-current electroporation technique was used to immunize mice with an intramuscular injection of plasmid coding for the extracellular and transmembrane domains of the product of the rat neu 664V-E oncogene protein. In wild-type BALB/c mice, plasmid electroporation at lower current settings elicits higher antibody titers, a strong cytotoxic response and completely protects all mice vaccinated with 10, 25 and 50 μg of plasmid against a lethal challenge of rat neu+ carcinoma cells. BALB/c mice transgenic for the transforming rat neu 664V-E (ErbB-2, Her-2/neu) oncogene (BALB-neuT664V-E) develop an invasive mammary gland carcinoma by 20 weeks of age. Remarkably, when transgenic BALB-neuT664V-E mice were vaccinated at a 10- week interval with 50 μg of plasmid with 0.2 A electroporation, mice remained tumor free for more than a year. A single administration of plasmid associated with electroporation was enough to markedly delay carcinogenesis progression in mice with multiple microscopic invasive carcinomas, and keep about 50% of mice tumor free at one year of age. Thus, vaccination using a clinically relevant dose of plasmid encoding the extracellular and transmembrane domains of the neu oncogene delivered by electroporation prevents long-term tumor formation. These improvements in the efficacy of this cancer vaccine regimen vastly increase its chances for clinical success.
DNA immunization using constant-current electroporation affords long-term protection from autochthonous mammary carcinomas in cancer-prone transgenic mice / CURCIO C.; KHAN A.S.; AMICI A.; SPADARO M.; QUAGLINO E.; CAVALLO F.; FORNI G.; DRAGHIA-AKLI R.. - In: CANCER GENE THERAPY. - ISSN 0929-1903. - 15:2(2008), pp. 108-114.
Scheda prodotto non validato
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
| Titolo: | DNA immunization using constant-current electroporation affords long-term protection from autochthonous mammary carcinomas in cancer-prone transgenic mice |
| Autori: | |
| Data di pubblicazione: | 2008 |
| Rivista: | |
| Citazione: | DNA immunization using constant-current electroporation affords long-term protection from autochthonous mammary carcinomas in cancer-prone transgenic mice / CURCIO C.; KHAN A.S.; AMICI A.; SPADARO M.; QUAGLINO E.; CAVALLO F.; FORNI G.; DRAGHIA-AKLI R.. - In: CANCER GENE THERAPY. - ISSN 0929-1903. - 15:2(2008), pp. 108-114. |
| Abstract: | A recently developed, adaptive constant-current electroporation technique was used to immunize mice with an intramuscular injection of plasmid coding for the extracellular and transmembrane domains of the product of the rat neu 664V-E oncogene protein. In wild-type BALB/c mice, plasmid electroporation at lower current settings elicits higher antibody titers, a strong cytotoxic response and completely protects all mice vaccinated with 10, 25 and 50 μg of plasmid against a lethal challenge of rat neu+ carcinoma cells. BALB/c mice transgenic for the transforming rat neu 664V-E (ErbB-2, Her-2/neu) oncogene (BALB-neuT664V-E) develop an invasive mammary gland carcinoma by 20 weeks of age. Remarkably, when transgenic BALB-neuT664V-E mice were vaccinated at a 10- week interval with 50 μg of plasmid with 0.2 A electroporation, mice remained tumor free for more than a year. A single administration of plasmid associated with electroporation was enough to markedly delay carcinogenesis progression in mice with multiple microscopic invasive carcinomas, and keep about 50% of mice tumor free at one year of age. Thus, vaccination using a clinically relevant dose of plasmid encoding the extracellular and transmembrane domains of the neu oncogene delivered by electroporation prevents long-term tumor formation. These improvements in the efficacy of this cancer vaccine regimen vastly increase its chances for clinical success. |
| Handle: | http://hdl.handle.net/11581/112528 |
| Appare nelle tipologie: | Articolo |
File in questo prodotto:
http://hdl.handle.net/11581/112528
Copyright © 2021